Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19-Reference-Cited by-同舟云学术

Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19

Published:2021-08-31 Issue:6 Volume:14 Page:2556-2565
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Pfeifer Nathan D.¹,Lo Arthur¹,Bourdet David L.¹,Colley Kenneth¹,Singh Dave²

Affiliation:

1. Theravance Biopharma US, Inc. South San Francisco California USA

2. Medicines Evaluation Unit University of ManchesterManchester University Manchester UK

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13123

Reference24 articles.

1. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

2. The pathophysiology of ‘happy’ hypoxemia in COVID-19

3. Lung Histopathology in Coronavirus Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1 Influenza

4. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

5. JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and clinical application of small-molecule inhibitors of Janus kinase;European Journal of Medicinal Chemistry;2023-12

2. Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization;Journal of Medicinal Chemistry;2023-09-22

3. Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review;Frontiers in Pharmacology;2023-03-20

4. Small molecules in the treatment of COVID-19;Signal Transduction and Targeted Therapy;2022-12-05

5. COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy;Frontiers in Medicine;2022-08-30